Abstract

8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 31/25 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
• A61P 17/06 - Antipsoriatics
• A61P 37/02 - Immunomodulators
• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/225 - Polycarboxylic acids

Abstract

8 alkyl alcohols.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A23L 33/12 - Fatty acids or derivatives thereof
• A23L 33/16 - Inorganic salts, minerals or trace elements
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/20 - Pills, lozenges or tablets
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• A23L 33/115 - Fatty acids or derivatives thereof; Fats or oils
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention relates to an agent for use in the treatment of patients suffering from systemic inflammatory symptoms and oxidative stress caused by end stage renal disease. Said agent contains a short-chain fatty acid having 3 to 6 carbon atoms or a physiologically acceptable derivative thereof as an active ingredient.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The invention relates to an agent for use in the prophylaxis or treatment of dyslipidemia, in particular for the treatment of excessive/elevated LDL levels, containing propionic acid or a physiologically acceptable propionic acid derivative.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 3/06 - Antihyperlipidemics
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Abstract

8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 31/25 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
• A61P 17/06 - Antipsoriatics
• A61P 37/02 - Immunomodulators
• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/225 - Polycarboxylic acids

Abstract

The invention relates to an agent for use in the prophylaxis or treatment of dyslipidemia, in particular for the treatment of excessive LDL values, said agent containing propionic acid or a physiologically acceptable propionic acid derivative.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 3/06 - Antihyperlipidemics

Abstract

The invention relates to a combination for use in the treatment of immune-mediated chronic inflammatory diseases and auto-immune diseases from C3,-8-carboxylic acids, to the physiologically acceptable salts and/or esters thereof as well as one or more fumaric acid esters and/or salts thereof, and to the use in the treatment of psoriasis and multiple sclerosis.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 37/02 - Immunomodulators
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 31/25 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol

Goods & Services

Chemical additives for food. Nutritional supplements; pharmaceuticals.

Goods & Services

Chemical additives for food. Nutritional supplements; pharmaceuticals.

Abstract

The invention relates to a supporting immunomodulatory agent for use in autoimmune diseases, containing C3-C8 carboxylic acids, the physiologically acceptable salts and/or esters with C1-C8 alkyl alcohols thereof, to the use of said carboxylic acids, salts and/or esters as supporting immunomodulators in autoimmune diseases and in chronic immune-mediated inflammatory diseases, and to food supplements having immunomodulatory effect and containing same.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 37/02 - Immunomodulators

Goods & Services

Nutritional supplements, namely, propionic acid and propionic acid derivatives, in particular propionates; pharmaceuticals, namely, for the treatment of intestinal, metabolic, cardiovascular and autoimmunological disorders

Goods & Services

Nutritional supplements; medicine.